2023-05-04 05:41:30 ET
- Novartis' ( NYSE: NVS ) unit Sandoz signed a distribution agreement with Adalvo to get exclusive rights to commercialize six products in the U.S. in areas of antifungal/antibiotic, cancer and pulmonary.
- These products from Adalvo are slated for near- to mid-term launches, starting in 2024 with four out of six expected to be first-to-market.
- "Sandoz is putting patients first by securing the rights to bring more affordable, equally effective treatments for a range of disorders that collectively affect millions of people in the US every year," said Keren Haruvi, President, Sandoz.
- The Swiss pharma giant is on track for the spin-off of the generic and biosimilars unit Sandoz in H2 2023. In August 2022, Novartis said it was going to spin off Sandoz into a separate publicly traded standalone company to focus on innovative medicines.
For further details see:
Novartis' Sandoz inks pact to exclusively sell 6 products in US